Chameleon Biosciences is transforming gene therapy with a re-dosable, AAV based gene therapy.
Chameleon Biosciences's investors include Matrix Partners China, SkyDeck Berkeley, Cantos, Berkeley SkyDeck Fund, Tachyon Ventures.
Chameleon Biosciences is headquartered in San Anselmo, United States.
Chameleon Biosciences is transforming gene therapy with a re-dosable, AAV based gene therapy.
Chameleon Biosciences is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Chameleon Biosciences — Funding & Investors." VCBacked, November 1, 2022, https://www.vcbacked.co/company/chameleon-biosciences. Accessed September 30, 2026.
VCBacked. (2022). Chameleon Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/chameleon-biosciences
{{cite web |title=Chameleon Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/chameleon-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated